Sight Sciences Inc (SGHT) Stock Price, Quote & News

Company Profile

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases in the United States. The company operates in two segments, Surgical Glaucoma and Dry Eye. It offers OMNI, a surgical system family of products, such as OMNI Ergo for the catheterization and transluminal viscodilation of Schlemm's canal and cutting of the trabecular meshwork to reduce intraocular pressure...

Industry: Medical Devices

Sector: Healthcare

Phone: 877 266 1144

Fax: 650 352 4401

Website: www.sightsciences.com

Address:

4040 Campbell Avenue, Suite 100, Menlo Park, United States

TonySuprano May. 8 at 12:37 AM

$SGHT decent close i guess ttomorrow more green

0 · Reply

focafoca99 May. 6 at 8:48 PM

$SGHT shared its first-quarter 2026 results and an investor presentation.

0 · Reply

StocktwitsEarnings May. 6 at 8:15 PM

$SGHT Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.24 up 14.29% YoY • Reported revenue of $19.7M up 12.51% YoY • Sight Sciences raised its full year 2026 revenue guidance to $83.0 million-$89.0 million, representing 7%-15% growth, and reaffirmed adjusted operating expenses guidance at $93.0 million-$96.0 million.

0 · Reply

buckdatrend13 May. 1 at 7:52 PM

$SGHT Nice move...but not much volume.

0 · Reply

BillionerOfKing Apr. 28 at 12:59 AM

$SGHT Current Stock Price: $4.32 Contracts to trade: $5.0 SGHT May 15 2026 Call Entry: $0.05 Exit: $0.08 ROI: 52% Hold ~27 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

BryGuy29 Apr. 23 at 10:32 PM

$SGHT bizarre day. $2.8 million volume and up only 5 cents?

0 · Reply

TitanTradeBeacon Apr. 23 at 5:28 PM

$SGHT benefits from increasing focus on operational automation and advanced infrastructure security. AI-powered protection improves efficiency while reducing long-term costs, and AITX continues showing strong market relevance with autonomous security towers securing major commercial operations.

0 · Reply

HyperVi Apr. 23 at 4:03 PM

$SGHT one hell of crazy stock

0 · Reply

OpportunityAbounds Apr. 23 at 3:56 PM

$SGHT I’m in

0 · Reply

OpportunityAbounds Apr. 23 at 3:17 PM

$SGHT Hmmm…

0 · Reply

Sight Sciences reports Q1 EPS (24c), consensus (20c)

2026-05-07T00:47:54.000Z - 6 days ago

Sight Sciences raises FY26 revenue view to $83M-$89M from $82M-$88M

May 6, 2026, 4:30 PM EDT - 6 days ago

Sight Sciences Earnings Call Transcript: Q1 2026

May 6, 2026, 4:05 PM EDT - 6 days ago

Sight Sciences Reports First Quarter 2026 Financial Results and Raises Full Year 2026 Revenue Guidance

Apr 29, 2026, 4:05 PM EDT - 13 days ago

Sight Sciences to Present at Two Upcoming Investor Conferences

Apr 22, 2026, 4:45 PM EDT - 20 days ago

Sight Sciences Announces the Release of its Sustainability Report

Apr 21, 2026, 4:05 PM EDT - 21 days ago

Sight Sciences to Report First Quarter 2026 Financial Results on May 6, 2026

Apr 13, 2026, 2:15 PM EDT - 4 weeks ago

Sight Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference

2026-04-07T10:56:28.000Z - 5 weeks ago

Sight Sciences price target lowered to $4.35 from $5 at Citi

$Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting$

Apr 1, 2026, 4:05 PM EDT - 5 weeks ago

Sight Sciences' Interventional Technologies for Glaucoma and Dry Eye Disease to be Featured in Multiple Clinical Presentations at the 2026 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Mar 30, 2026, 4:05 PM EDT - 6 weeks ago

Sight Sciences to Present at the 25th Annual Needham Healthcare Conference on April 13th

2026-03-30T11:30:29.000Z - 6 weeks ago

Sight Sciences awarded monetary damages by district court against Alcon

ALC

Mar 30, 2026, 7:05 AM EDT - 6 weeks ago

Sight Sciences Secures Order on Post-Trial Motions That Preserves the Jury's Verdict and Awards Monetary Damages to Sight Sciences Against Alcon and its Hydrus® Microstent

2026-03-11T09:25:10.000Z - 2 months ago

Sight Sciences price target lowered to $5 from $6.50 at Citi

Mar 6, 2026, 2:13 PM EST - 2 months ago

Sight Sciences Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

2026-03-06T11:37:05.000Z - 2 months ago

Sight Sciences price target lowered to $6.50 from $9.10 at Citi

2026-03-06T11:21:23.000Z - 2 months ago

Sight Sciences price target lowered to $11 from $12 at UBS

Mar 4, 2026, 4:30 PM EST - 2 months ago

Sight Sciences Earnings Call Transcript: Q4 2025

2026-03-04T21:27:54.000Z - 2 months ago

Sight Sciences reports Q4 EPS (8c), consensus (14c)

2026-03-04T21:26:13.000Z - 2 months ago

Sight Sciences sees FY26 revenue $82M-$88M, consensus $86.11M

Mar 4, 2026, 4:05 PM EST - 2 months ago

Sight Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Initiates Full Year 2026 Financial Guidance

2026-03-02T13:01:30.000Z - 2 months ago

Sight Sciences price target raised to $8 from $6 at Stifel

Feb 18, 2026, 4:05 PM EST - 2 months ago

Sight Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026

2026-01-30T12:21:13.000Z - 3 months ago

Sight Sciences resumed with an Outperform at William Blair

2026-01-13T12:11:02.000Z - 4 months ago

Sight Sciences reports preliminary Q4 revenue $20.3M-$20.4M, consensus $20.17M

2026-01-13T12:10:53.000Z - 4 months ago

Sight Sciences reports preliminary FY25 revenue $77.3M-$77.4M

Jan 13, 2026, 7:05 AM EST - 4 months ago

Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Highlights

2026-01-05T11:35:25.000Z - 4 months ago

Piper Sandler upgrades Sight Sciences to Overweight, raises target to $9

2026-01-05T11:01:13.000Z - 4 months ago

Sight Sciences upgraded to Overweight from Neutral at Piper Sandler

2025-12-23T12:06:07.000Z - 5 months ago

Sight Sciences price target raised to $12 from $7 at UBS

2025-12-23T00:55:11.000Z - 5 months ago

Sight Sciences price target raised to $12 from $7 at UBS

2025-12-11T11:20:57.000Z - 5 months ago

Sight Sciences price target raised to $9.10 from $5.50 at Citi

Nov 11, 2025, 11:20 AM EST - 6 months ago

Sight Sciences Transcript: Stifel 2025 Healthcare Conference

Nov 6, 2025, 4:30 PM EST - 6 months ago

Sight Sciences Earnings Call Transcript: Q3 2025

Nov 6, 2025, 4:05 PM EST - 6 months ago

Sight Sciences Reports Third Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Nov 6, 2025, 4:04 PM EST - 6 months ago

Sight Sciences Appoints Ali Bauerlein as Chief Operating Officer and Jim Rodberg as Chief Financial Officer

Oct 23, 2025, 4:05 PM EDT - 7 months ago

Sight Sciences to Report Third Quarter 2025 Financial Results on November 6, 2025

Oct 17, 2025, 7:00 AM EDT - 7 months ago

Sight Sciences Announces Fee Schedule Establishment from Novitas Solutions and First Coast Service Options for the TearCare® Interventional Dry Eye Procedure

Sep 17, 2025, 7:00 AM EDT - 8 months ago

Sight Sciences Announces Publication of a Systematic Literature Review and Meta-Analysis Showing OMNI® Surgical System Achieves Clinically Significant, Long-Term Reductions in IOP and Medication Use

Sep 10, 2025, 1:50 PM EDT - 8 months ago

Sight Sciences Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 7:05 AM EDT - 8 months ago

Sight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical Treatments

Sep 2, 2025, 4:05 PM EDT - 9 months ago

Sight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJO

Aug 26, 2025, 4:05 PM EDT - 9 months ago

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Sight Sciences Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Sight Sciences Reports Second Quarter 2025 Financial Results and Raises Full Year 2025 Revenue Guidance

Jul 30, 2025, 7:00 AM EDT - 10 months ago

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% for Treating Meibomian Gland Disease-Associated Dry Eye Disease

Jul 29, 2025, 7:00 AM EDT - 10 months ago

Sight Sciences Announces the Publication of the 24-Month Results of the SAHARA RCT Demonstrating the Durability of the TearCare® Procedure for the Treatment of Dry Eye Disease

Jul 24, 2025, 4:05 PM EDT - 10 months ago

Sight Sciences to Report Second Quarter 2025 Financial Results on August 7, 2025

May 27, 2025, 12:00 PM EDT - 1 year ago

Sight Sciences Transcript: Stifel 2025 Virtual Ophthalmology Forum

May 14, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

May 8, 2025, 4:30 PM EDT - 1 year ago

Sight Sciences Earnings Call Transcript: Q1 2025

May 8, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

Apr 24, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences Appoints Gary Burbach to its Board of Directors

Apr 21, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Debut OMNI® Edge Surgical System at the 2025 ASCRS Annual Meeting, Expanding the OMNI Product Portfolio

Apr 8, 2025, 3:45 PM EDT - 1 year ago

Sight Sciences Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 25, 2025, 4:05 PM EDT - 1 year ago

Sight Sciences to Present at the 24th Annual Needham Healthcare Conference on April 8th

Mar 5, 2025, 4:30 PM EST - 1 year ago

Sight Sciences Earnings Call Transcript: Q4 2024

Mar 5, 2025, 4:05 PM EST - 1 year ago

Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

Feb 27, 2025, 10:15 AM EST - 1 year ago

Sight Sciences Transcript: Citi’s 2025 Medtech and Life Sciences Access Day

Feb 24, 2025, 4:05 PM EST - 1 year ago

Sight Sciences to Present Comprehensive Clinical Data on the OMNI® Surgical System at the 2025 American Glaucoma Society Annual Meeting

Feb 19, 2025, 4:05 PM EST - 1 year ago

Sight Sciences to Report Fourth Quarter and Full Year 2024 Financial Results on March 5, 2025

Feb 13, 2025, 4:05 PM EST - 1 year ago

Sight Sciences to Present at Citi's 2025 Unplugged MedTech and Life Sciences Access Day

Dec 19, 2024, 4:05 PM EST - 1 year ago

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

Dec 3, 2024, 3:30 PM EST - 1 year ago

Sight Sciences Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 19, 2024, 4:05 PM EST - 1 year ago

Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 7, 2024, 4:30 PM EST - 1 year ago

Sight Sciences Earnings Call Transcript: Q3 2024

Oct 17, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

Oct 14, 2024, 4:05 PM EDT - 1 year ago

Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

Sep 4, 2024, 4:50 PM EDT - 1 year ago

Sight Sciences Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 1, 2024, 4:30 PM EDT - 1 year ago

Sight Sciences Earnings Call Transcript: Q2 2024

Jul 18, 2024, 4:05 PM EDT - 1 year ago

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

Jun 10, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Release of its First Sustainability Report

May 28, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

May 28, 2024, 8:30 AM EDT - 2 years ago

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

May 14, 2024, 11:15 AM EDT - 2 years ago

Sight Sciences Transcript: BofA Securities 2024 Health Care Conference

May 2, 2024, 4:30 PM EDT - 2 years ago

Sight Sciences Earnings Call Transcript: Q1 2024

May 2, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

Apr 29, 2024, 8:05 AM EDT - 2 years ago

Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

Apr 18, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences to Report First Quarter Financial Results on May 2, 2024

Apr 10, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2

Apr 9, 2024, 3:45 PM EDT - 2 years ago

Sight Sciences Transcript: 23rd Annual Needham Virtual Healthcare Conference

$Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting$

Apr 2, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

Mar 26, 2024, 4:05 PM EDT - 2 years ago

Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

Mar 7, 2024, 4:30 PM EST - 2 years ago

Sight Sciences Earnings Call Transcript: Q4 2023

Mar 7, 2024, 4:05 PM EST - 2 years ago

Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance

Feb 22, 2024, 4:05 PM EST - 2 years ago

Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024

Feb 14, 2024, 4:05 PM EST - 2 years ago

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting

TonySuprano May. 8 at 12:37 AM

$SGHT decent close i guess ttomorrow more green

0 · Reply

focafoca99 May. 6 at 8:48 PM

$SGHT shared its first-quarter 2026 results and an investor presentation.

0 · Reply

StocktwitsEarnings May. 6 at 8:15 PM

0 · Reply

buckdatrend13 May. 1 at 7:52 PM

$SGHT Nice move...but not much volume.

0 · Reply

BillionerOfKing Apr. 28 at 12:59 AM

0 · Reply

BryGuy29 Apr. 23 at 10:32 PM

$SGHT bizarre day. $2.8 million volume and up only 5 cents?

0 · Reply

TitanTradeBeacon Apr. 23 at 5:28 PM

0 · Reply

HyperVi Apr. 23 at 4:03 PM

$SGHT one hell of crazy stock

0 · Reply

OpportunityAbounds Apr. 23 at 3:56 PM

$SGHT I’m in

0 · Reply

OpportunityAbounds Apr. 23 at 3:17 PM

$SGHT Hmmm…

0 · Reply

SmartMoneyTradez Apr. 23 at 2:54 PM

$SGHT They are loading up and covering. Dont !tch if you get left behind $CAR $BURU $AMD $BTC.X

0 · Reply

BryGuy29 Apr. 23 at 2:51 PM

$SGHT something is up here. 🤔

0 · Reply

SmartMoneyTradez Apr. 23 at 2:41 PM

$SGHT ghost town here. 5x volume

0 · Reply

focafoca99 Apr. 23 at 5:44 AM

$SGHT published its annual sustainability report covering progress over the last three years.

0 · Reply

ko_my_money Apr. 20 at 4:25 PM

$SGHT

0 · Reply

2TrustHim Apr. 14 at 2:27 PM

$SGHT $OCGN Interesting Company!!! https://www.sightsciences.com/

1 · Reply

focafoca99 Apr. 1 at 9:47 PM

$SGHT is using ASCRS to showcase new OMNI and TearCare data, including TearCare results that beat Restasis on tear-film stability measures.

1 · Reply

buckdatrend13 Apr. 1 at 2:07 PM

$SGHT Possible reverse head and shoulders forming on the daily chart.

0 · Reply

DARKP00L Mar. 30 at 11:27 AM

$SGHT 07:09 on Mar. 30 2026 U.S. District Court Preserves Jury's Willful Infringement Verdict In Sight Sciences Case Vs Alcon #tradeideas

0 · Reply

DARKP00L Mar. 30 at 11:13 AM

$SGHT 07:09 on Mar. 30 2026 U.S. District Court Preserves Jury's Willful Infringement Verdict In Sight Sciences Case Vs Alcon #tradeideas

0 · Reply

OfficialStocktwitsUser Mar. 21 at 12:03 AM

$SGHT RSI: 21.33, MACD: -0.5907 Vol: 0.80, MA20: 4.38, MA50: 5.44 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

buckdatrend13 Mar. 14 at 10:51 AM

$SGHT Inverted hammer created after downtrend on the weekly chart. A higher close this time next week will likely signal a trend reversal.

0 · Reply

Market Cap	288.92M
Revenue (ttm)	77.36M
Net Income (ttm)	-38.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-49.68%
Debt to Equity Ratio	0.75

Volume	307,500
Avg Vol	358,170
Day's Range	N/A - N/A
Shares Out	54.41M
Stochastic %K	60%
Beta	2.38
Analysts	Strong Sell
Price Target	$8.34